Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,017,154 shares of NBIX stock, worth $128 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,017,154

Previous 1,132,589 10.19%

Holding current value

$128 Million

Previous $156 Million 24.9%

% of portfolio

0.02%

Previous 0.03%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $13.2 Million - $17.7 Million	-115,435 Reduced 10.19%	1,017,154 $117 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $46.7 Million - $51.1 Million	356,862 Added 46.0%	1,132,589 $156 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $11 Million - $12.1 Million	84,095 Added 12.16%	775,727 $107 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $10.1 Million - $12.7 Million	-95,323 Reduced 12.11%	691,632 $91.1 Million
Q3 2023 May 14, 2024	BUY	$94.02 - $117.1 $8.96 Million - $11.2 Million	95,323 Added 13.78%	786,955 $88.5 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $3.54 Million - $4.41 Million	-37,682 Reduced 4.57%	786,955 $88.5 Million
Q2 2023 May 14, 2024	SELL	$89.53 - $104.87 $13 Million - $15.2 Million	-145,163 Reduced 14.97%	824,637 $77.8 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $13 Million - $15.2 Million	-145,163 Reduced 14.97%	824,637 $77.8 Million
Q1 2023 May 14, 2024	SELL	$94.11 - $123.02 $33.9 Million - $44.3 Million	-359,922 Reduced 27.07%	969,800 $98.2 Million
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $33.9 Million - $44.3 Million	-359,922 Reduced 27.07%	969,800 $98.2 Million
Q4 2022 May 14, 2024	BUY	$106.72 - $127.06 $13.7 Million - $16.3 Million	127,932 Added 10.65%	1,329,722 $159 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $13.7 Million - $16.3 Million	127,932 Added 10.65%	1,329,722 $159 Million
Q3 2022 May 14, 2024	SELL	$92.03 - $107.81 $4.88 Million - $5.72 Million	-53,033 Reduced 4.23%	1,201,790 $128 Million
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $4.88 Million - $5.72 Million	-53,033 Reduced 4.23%	1,201,790 $128 Million
Q2 2022 May 14, 2024	BUY	$75.79 - $100.07 $42.7 Million - $56.4 Million	563,191 Added 81.43%	1,254,823 $122 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $18.3 Million - $24.2 Million	-241,629 Reduced 16.15%	1,254,823 $122 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $2.03 Million - $2.66 Million	-28,063 Reduced 1.84%	1,496,452 $140 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $6.45 Million - $8.61 Million	81,017 Added 5.61%	1,524,515 $130 Million
Q3 2021 Nov 10, 2021	BUY	$86.18 - $99.03 $124 Million - $143 Million	1,443,498 New	1,443,498 $138 Million

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94.3M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History